Table 3.
Immune responses by ELISPOT and by flow cytometry
| Patient ID VMM | Study group | ELISPOT response | Multifunctional | CD4+ TNF-α+ and/or IFN-γ+ | CD8+ TNF-α+ and/or IFN-γ+ | |
|---|---|---|---|---|---|---|
| CD4+ TNF-α+IFN-γ+ | CD8+ TNF-α+IFN-γ+ | |||||
| 1075 | A | SIN | SIN | – | SIN | – |
| 1079 | A | – | – | – | SIN | – |
| 1080 | A | SIN | SIN | – | SIN | 13 |
| 1082 | A | – | 1 | – | – | – |
| 1087 | A | – | 7 | – | – | – |
| 1091 | A | – | 13 | – | – | – |
| 1094 | A | – | (13, 26) | – | – | – |
| 1100 | A | – | – | 1, (26) | – | – |
| 1103 | A | – | – | – | – | – |
| 1107 | A | – | – | – | – | – |
| 1109 | A | SIN | 7, SIN | – | SIN | – |
| 1110 | A | – | – | – | – | – |
| 1117 | A | SIN | SIN | – | SIN | – |
| 1073 | B | – | 1 | – | 1 (7) | – |
| 1076 | B | 1, SIN | SIN | SIN | – | – |
| 1077 | B | SIN | 1, (7, 13), SIN | – | (1, 13), SIN | – |
| 1078 | B | – | SIN | 1 | SIN | 1 |
| 1086 | B | – | (1) 7, 13, SIN | – | (1, 7, 13), SIN | – |
| 1089 | B | – | – | – | 26 | – |
| 1093 | B | – | – | – | – | – |
| 1095a | B | a | – | – | – | – |
| 1098 | B | – | SIN | 26 | SIN | 26 |
| 1106b | B | b | b; 13 | b | b | b |
| 1112 | B | SIN | 7, 13, SIN | – | SIN | – |
| 1113 | B | – | (13), 26, SIN | – | (13, 26), SIN | – |
| T cell response in SIN | A | 4/13 (31 %) | 4/13 (31 %) | 0/13 (0 %) | 5/13 (38 %) | 0/13 (0 %) |
| B | 3/10 (30 %) | 7/11 (64 %) | 1/11 (9 %) | 6/11 (55 %) | 0/11 (0 %) | |
| All | 7/23 (30 %) | 11/24 (46 %) | 1/24 (4 %) | 11/24 (46 %) | 0/24 (0 %) | |
| T cell response in PBMC | A | 0/13 (0 %) | 4/13 (31 %) | 1/13 (8 %) | 0/13 (0 %) | 1/13 (8 %) |
| B | 1/12 (8 %) | 6/12 (50 %) | 2/12 (17 %) | 2/12 (17 %) | 2/12 (17 %) | |
| All | 1/25 (4 %) | 10/25 (40 %) | 3/25 (12 %) | 2/25 (8 %) | 3/25 (12 %) | |
| T cell response in SIN and PBMC | A | 0/13 (0 %) | 1/13 (8 %) | 0/13 (0 %) | 0/13 (0 %) | 0/13 (0 %) |
| B | 1/10 (10 %) | 4/11 (36 %) | 0/11 (0 %) | 0/11 (0 %) | 0/11 (0 %) | |
| All | 1/23 (4 %) | 5/24 (21 %) | 0/24 (0 %) | 0/24 (0 %) | 0/24 (0 %) | |
| T cell response in SIN or PBMC | A | 4/13 (31 %) | 7/13 (54 %) | 1/13 (8 %) | 5/13 (38 %) | 1/13 (8 %) |
| B | 3/12 (25 %) | 9/12 (75 %) | 3/12 (25 %) | 8/12 (67 %) | 2/12 (17 %) | |
| All | 7/25 (28 %) | 16/25 (64 %) | 4/25 (16 %) | 13/25 (52 %) | 3/25 (12 %) | |
Responses are denoted by the week in which the response was observed from PBMC, or by the presence of a response in the SIN (e.g., 13, SIN = response in PBMC week 13, and in the SIN). Weeks marked in parentheses [e.g., (13)] represent weeks in which a fold increase of 1.5–2 when at least one other time point met criteria for positivity (2x)
aSIN ELISPOT not done for VMM1095; b SIN not done for VMM1106; NE not evaluable